Company intelligence / Profile preview

Imbria Pharmaceuticals

Boston, Massachusetts, United Statesimbria.com ↗

Ownership: Private
Development stage: Other

Overview

Imbria’s lead candidate ninerafaxstat has demonstrated positive results in multiple Phase 2 clinical trials across three indications—non-obstructive hypertrophic cardiomyopathy (nHCM), stable angina, and HFpEF. In nHCM patients, it was the first investigational drug to show improvement in functional measures by exercise testing and patient-reported symptoms. In HFpEF patients, it improved cardiac energetics and physical limitations. The drug has been well tolerated to date.

Therapeutic areas: Cardiovascular
Modalities: small molecules (notably partial fatty acid oxidation inhibitors)
Industry: Biotech

Drug pipeline

2 assets

ninerafaxstat

1 more asset in the full pipeline.

Partnerships

Cytokinetics participated as an investor; no major disclosed pharma partnerships beyond investment syndicate.

Beyond the preview

Go deeper on Imbria Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imbria Pharmaceuticals.